Skip to main content
Haisco Pharmaceutical Group Co.,Ltd logo

Haisco Pharmaceutical Group Co.,Ltd — Investor Relations & Filings

Ticker · 002653 ISIN · CNE100001BC7 LEI · 300300GRLH34A8GPJ639 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,439 across all filing types
Latest filing 2023-08-16 Interim / Quarterly Rep…
Country CN China
Listing Shenzhen Stock Exchange 002653

About Haisco Pharmaceutical Group Co.,Ltd

https://www.haisco.com

Haisco Pharmaceutical Group Co.,Ltd. focuses on the research, development, production, and commercialization of innovative drugs and high-end generic pharmaceuticals. The company maintains a specialized portfolio across therapeutic areas including anesthesia, parenteral nutrition, anti-infection, cardiovascular health, and endocrine disorders. Key products include advanced anesthetic agents and specialized nutritional injections designed for clinical use. Haisco prioritizes technological innovation through a dedicated R&D infrastructure, targeting the development of small molecule chemical drugs and complex delivery systems. Its operations emphasize high-standard manufacturing processes and the integration of clinical research to address complex medical requirements. The company aims to provide therapeutic solutions that enhance patient care through a commitment to scientific excellence and product quality.

Recent filings

Filing Released Lang Actions
半年度非经营性资金占用及其他关联资金往来情况汇总表
Interim / Quarterly Report Classification · 90% confidence The document is a summary table detailing non-operating fund occupation and other related party fund transactions for the first half of 2023 by Haise Medical Group Co., Ltd. It contains financial data for the half-year period, including balances, amounts occupied, interest, repayments, and ending balances. The content is financial and operational in nature, covering a period shorter than a full fiscal year (half-year). It is not an announcement or a brief summary but contains substantive financial data and analysis for the half-year period. Therefore, it fits the definition of an Interim / Quarterly Report (IR). The document length is short but contains actual financial data, not just a notice or certification, so it is not RPA or RNS. H1 2023
2023-08-16 Chinese
独立董事关于控股股东及其他关联方占用公司资金、公司对外担保情况的专项说明和独立意见
Audit Report / Information Classification · 95% confidence The document is an independent director's opinion on related matters, specifically addressing the company's related party fund occupation and external guarantees for subsidiaries during the 2023 half-year period. It references compliance with listing rules and company articles, and provides an independent opinion rather than presenting full financial statements or detailed audit results. The document length is short (914 characters) and it does not contain comprehensive financial data or audit findings. It is a standalone opinion related to governance and compliance matters, not a full audit report or annual/interim report. Therefore, it fits best under Audit Report / Information (AR), which includes standalone audit reports, applied accounting principles, and related regulatory or compliance opinions excluding full annual reports. H1 2023
2023-08-16 Chinese
关于获得创新药HSK34890片《药物临床试验批准通知书》的公告
Regulatory Filings Classification · 95% confidence The document is an official announcement from a pharmaceutical company about receiving approval for a clinical trial of a new drug (HSK34890). It includes details about the drug, regulatory approval, and risk warnings. The document is short (1138 characters) and serves as a public disclosure of a regulatory milestone rather than a financial report or detailed management discussion. It does not contain financial statements, earnings data, or management analysis. It is not a report of voting results, board changes, or capital updates. The content fits best as a Regulatory Filing (RNS) because it is a regulatory announcement about drug trial approval, which does not fit other specific categories.
2023-08-13 Chinese
提名人声明（乐军）
Board/Management Information Classification · 95% confidence The document is a public statement from the board of directors nominating an individual as an independent director candidate for the company's next board. It details the nominee's qualifications, compliance with various regulatory requirements, and declarations regarding independence and eligibility. There is no financial data, no report of financial performance, no voting results, no management changes announcement, and no mention of any report publication. The content is focused on board/management information specifically related to the nomination of a board member. Therefore, the document fits best under the category of Board/Management Information (MANG). The document length is about 5,049 characters, which is sufficient for a detailed nomination statement rather than a brief announcement.
2023-08-09 Chinese
独立董事候选人声明(岳琳)
Board/Management Information Classification · 95% confidence The document is a public statement by an independent director candidate of a company, declaring compliance with various legal and regulatory requirements for serving as an independent director. It includes detailed attestations about qualifications, independence, and absence of conflicts of interest. There is no financial data, no discussion of company performance, no voting results, no meeting materials, and no mention of report publication. The document is a declaration related to board/management information, specifically about the appointment or candidacy of an independent director. Therefore, it fits best under the category of Board/Management Information (MANG). The document length is moderate and contains detailed statements, not a brief announcement or certification, so it is not Regulatory Filings (RNS).
2023-08-09 Chinese
提名人声明（岳琳）
Board/Management Information Classification · 95% confidence The document is a formal public statement from the board of directors nominating an individual as an independent director candidate for the company's next board. It includes detailed declarations about the nominee's qualifications, compliance with relevant laws and regulations, and independence criteria. There is no financial data, earnings information, or report content. The document is an announcement related to board/management changes, specifically a nomination for a board position. Therefore, it fits the category of Board/Management Information (MANG). The document length is about 5,000 characters, consistent with a detailed announcement rather than a full report.
2023-08-09 Chinese

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.